The North America oral mucositis market was valued at USD 546.75 Million in 2025 and is expected to grow at a CAGR of 6.90%, reaching USD 1065.53 Million by 2035. The market is gaining traction with the introduction of advanced topical formulations and pain management solutions for cancer-induced mucositis. Enhanced focus on patient quality of life and rising healthcare expenditure are encouraging adoption. Ongoing research into anti-inflammatory and mucosal healing agents continues to support long-term growth across clinical settings.
Base Year
Historical Period
Forecast Period
In the United States, an estimated 500,000–1,000,000 patients develop oral mucositis annually, significantly driving market growth as the rising incidence among cancer patients increases the demand for effective therapeutic and preventive treatments.
In November 2023, BioSyent Pharma Inc. launched Gelclair® in Canada for relieving oral mucositis pain in cancer patients. The product’s approval and availability are expected to enhance treatment accessibility and drive market growth across North America.
The market is experiencing steady growth driven by rising cancer cases, increasing adoption of advanced therapeutic solutions, and strong contributions from key players focusing on innovative treatment options and improved patient care outcomes.
Compound Annual Growth Rate
6.9%
Value in USD Million
2026-2035
*this image is indicative*
Oral mucositis frequently develops as a side effect of cancer therapies, causing severe pain and difficulty in eating or speaking. In North America, the market was valued at USD 546.75 Million in 2025. It is growing steadily, supported by increasing cancer incidence, a strong focus on patient-centric care, and expanded use of advanced therapeutic interventions. Ongoing research collaborations, improved access to preventive solutions, and technological innovations in phototherapy and mucosal healing products are strengthening the region’s market performance and clinical adoption rates.
Rising Cancer Incidence to Drive the Market Growth in North America
The growing incidence of cancer across North America is a key driver of the oral mucositis market. For instance, in January 2025, PubMed Central reported that approximately 2,041,910 new invasive cancer cases are projected to be diagnosed in the United States, averaging about 5,600 cases daily. As chemotherapy and radiotherapy remain integral to cancer management, the associated risk of oral mucositis is increasing significantly. This surge in oncology cases is expected to elevate the demand for effective oral mucositis prevention and treatment solutions, thereby strengthening market growth across the region.
Some of the key trends in the market include advancements in oral cryotherapy devices and the development of innovative therapeutic approaches.
Strategic Collaborations Boosting the Market Value
Strategic collaborations are driving the adoption of advanced oral cryotherapy technologies aimed at alleviating chemotherapy-induced mucosal damage, thereby enhancing the overall market value. In September 2024, the collaboration between Sanara MedTech Inc. and InfuSystem Holdings, Inc. exemplified this trend through the exclusive U.S. distribution of an FDA-cleared oral cryotherapy device designed to reduce the severity of oral mucositis. The increasing adoption of such clinically validated and reimbursable therapeutic solutions is anticipated to enhance patient outcomes and significantly boost market growth in the coming years.
Increasing Therapeutic Innovations Bolstering the North America Oral Mucositis Market Demand
The market is witnessing an increasing focus on developing targeted therapies aimed at reducing the adverse effects of cancer treatments. In June 2024, clinical progress surrounding ST-617 by Supportive Therapeutics highlighted growing research interest in novel formulations designed to prevent and treat chemotherapy- and radiation-induced oral mucositis. Such advancements reflect a broader industry shift toward precision-driven supportive care, enhancing patient outcomes and quality of life. This innovation-driven momentum is expected to significantly boost market growth in the coming years.
Antibiotics Expected to Dominate the Market Share by Drug Class
The market is segmented by drug class into antibiotics, antifungal, anti-inflammatory, anti-neoplastic, and others. Each category contributes to managing infection, inflammation, and tissue damage during treatment. Among these, the antibiotics segment is anticipated to lead the market, driven by their essential role in preventing and treating secondary bacterial infections that commonly accompany mucosal damage. The growing use of broad-spectrum antibiotics and preventive antimicrobial therapies further supports their leading position in clinical management.
The market is divided into regions such as the United States and Canada. Among these, the United States market is expected to dominate, driven by high cancer prevalence and growing adoption of innovative supportive care products. In October 2024, Jaguar Health launched Gelclair, an FDA-approved oral mucositis prescription product through its subsidiary Napo Pharmaceuticals. This launch underscores the country’s strong focus on improving cancer supportive care. Gelclair’s introduction reflects the U.S. leadership in advancing effective pain management and quality-of-life solutions for oncology patients.
The key features of the market report comprise funding and investment analysis, clinical trials and pipeline analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Amgen Inc. is a significant player in the market and has strengthened its position through the approval and clinical success of Kepivance (palifermin). This therapy mitigates severe oral mucositis among patients with hematologic malignancies receiving intensive chemotherapy or radiation. The company’s science-driven approach and patient-centered innovations continue to support the region’s oncology care advancements and therapeutic outcomes.
Innovation Pharmaceuticals is actively involved in the market. In its Phase 2 clinical trial, the company reported that Brilacidin-OM markedly reduced the incidence of oral mucositis in patients recieving high-dose cisplatin therapy. The firm emphasizes statistically significant subgroup findings and acceptable safety profiles. With an FDA Fast Track designation and subsequent analysis informing study design, the company is pursuing regulatory and reimbursement pathways across North America. It is also assessing commercialization strategies to address an unmet clinical need for effective severe oral mucositis prevention.
Galera Therapeutics Inc. plays a vital role in advancing oncology supportive care through its innovative drug development. The company focuses on radiotherapy-induced toxicities, particularly oral mucositis, a serious condition affecting cancer patients undergoing radiation treatment. With its research-driven approach and expanding clinical programs, Galera aims to deliver effective and safe therapies that enhance patient comfort, reduce complications, and complement existing cancer treatment protocols.
Soligenix Inc. plays a key role in advancing oncology care through its focus on oral mucositis and related inflammatory conditions. The company’s work centers on strengthening immune defense and accelerating recovery for patients undergoing cancer therapy. Its commitment to scientific innovation and collaboration with clinical networks in the region reflects an effort to deliver effective therapeutic options for managing treatment-induced mucosal damage.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Monopar Therapeutics Inc., Oragenics Inc., Jaguar Health Inc., EpicentRx Inc., and Enzychem Lifesciences.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Country
Upto 15% Off
USD
$4299 $3869
$2699 $2429
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Country |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share